Apixaban Inhibits Progression of Experimental Diabetic Nephropathy by Blocking Advanced Glycation End Product-Receptor Axis
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26073007 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Takanori Matsui und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioscience and Biotechnology, Fukui Prefectural University, Eiheiji 910-1195, Japan. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Pyridones, Receptor for Advanced Glycation End Products, Pyrazoles. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb, Tokyo, Japan.
Abstract (Originalsprache)
Diabetes is associated with an increased risk of thromboembolism. However, the effects of apixaban, a factor Xa inhibitor on diabetic nephropathy, remain unknown. Six-week-old Wistar rats received a single 60 mg/kg intraperitoneal injection of streptozotocin to produce a model of type 1 diabetes. Type 1 diabetic and non-diabetic control rats were treated with or without apixaban orally for 8 weeks, and blood and kidneys were obtained for biochemical, real-time reverse transcription-polymerase chain reaction (RT-PCR) and morphological analyses. Although apixaban treatment did not affect glycemic or lipid parameters, it significantly (p < 0.01) inhibited the increases in advanced glycation end products (AGEs), the receptor for AGEs (RAGE) mRNA and protein levels, 8-hydroxy-2′-deoxyguanosine (8-OHdG), and NADPH oxidase-driven superoxide generation in diabetic rats at 14 weeks old. Compared with non-diabetic rats, gene and protein expression levels of monocyte chemoattractant protein-1 (MCP-1), vascular cell adhesion molecule-1 (VCAM-1), transforming growth factor-β (TGF-β), connective tissue growth factor (CTGF), and fibronectin were increased in 14-week-old diabetic rats, which were associated with enhanced renal expression of kidney injury molecule-1 (KIM-1) and Mac-3, increased extracellular matrix accumulation in the kidneys, and elevated urinary excretion levels of protein and KIM-1, all of which were significantly inhibited by the treatment with apixaban. Urine KIM-1 levels were significantly (p < 0.01) and positively correlated with AGEs (r = 0.690) and 8-OHdG (r = 0.793) in the kidneys and serum 8-OHdG levels (r = 0.823). Our present findings suggest that apixaban could ameliorate renal injury in streptozotocin-induced type 1 diabetic rats partly by blocking the AGE-RAGE-oxidative stress axis in diabetic kidneys.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioscience and Biotechnology, Fukui Prefectural University, Eiheiji 910-1195, Japan.
- Department of Pediatric Surgery, Kurume University School of Medicine, Kurume 830-0011, Japan.
- Department of Medicine, Division of Nephrology, Kurume University School of Medicine, Kurume 830-0011, Japan.
- Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University Graduate School of Medicine, Tokyo 142-8666, Japan.
ORCID-Profile: Takanori Matsui, Ami Sotokawauchi, Sho-Ichi Yamagishi
Förderung
- Bristol Myers Squibb, Tokyo, Japan
Zitieren
APA
Matsui, T., Sotokawauchi, A., Nishino, Y., Koga, Y., & Yamagishi, S. I. (2025). Apixaban Inhibits Progression of Experimental Diabetic Nephropathy by Blocking Advanced Glycation End Product-Receptor Axis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26073007
Vancouver
Matsui T, Sotokawauchi A, Nishino Y, Koga Y, Yamagishi SI. Apixaban Inhibits Progression of Experimental Diabetic Nephropathy by Blocking Advanced Glycation End Product-Receptor Axis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26073007
BibTeX
@article{Matsui2025,
author = {Matsui, Takanori and Sotokawauchi, Ami and Nishino, Yuri and Koga, Yoshinori and Yamagishi, Sho-Ichi},
title = {Apixaban Inhibits Progression of Experimental Diabetic Nephropathy by Blocking Advanced Glycation End Product-Receptor Axis},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26073007}
}
EUVIMED